about
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsSafety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndromeClinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.Visualising the cross-level relationships between pathological and physiological processes and gene expression: analyses of haematological diseasesMSI2 is required for maintaining activated myelodysplastic syndrome stem cells.Propagation of trimethylated H3K27 regulated by polycomb protein EED is required for embryogenesis, hematopoietic maintenance, and tumor suppression.Emerging biological therapies for the treatment of myelodysplastic syndromes.Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis.Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: A pilot study.Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients.Clinical and pathological correlations of marrow PUMA and P53 expressions in myelodysplastic syndromes.
P2860
Q24629306-5A01CCB7-4C29-4D4D-BF0C-FF1E77CAE114Q24632949-FE5097D1-B8B0-4D32-8DA6-D4C27527DA25Q27852437-35353FA4-BF0F-470B-B79E-4B0C5D5128E5Q30883788-288CF6D8-2072-4C92-8E89-EC82EF39AEB9Q33769072-01F8448A-9A65-4D82-B55D-2D4A5F565063Q33945004-A0A81E73-9350-4C00-821D-57056B2AE410Q34542542-BA45AE50-31F4-4ADB-A5B2-1F8482A6312DQ36611010-3C238746-D31D-43FE-9329-6B2A899E65EDQ37264244-0CF2BBA4-3484-4DC9-BBD8-2AB5F9CFCA72Q38834981-A1CD7C46-1FC9-446D-AA14-25455EE21A65Q41878939-79A2112D-F3C6-4E90-A97D-1F9FC4C35BE2Q46729480-1C2E1B56-4C6E-4A80-89E8-E36CEF2BF304Q48186090-E2FA9FDF-316E-4F45-A3D1-2E85CD249ED7Q52953408-3F2035AF-5C7C-4FA7-8740-0EA1E01C54E0
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Molecular biology of myelodysplastic syndromes.
@en
Molecular biology of myelodysplastic syndromes.
@nl
type
label
Molecular biology of myelodysplastic syndromes.
@en
Molecular biology of myelodysplastic syndromes.
@nl
prefLabel
Molecular biology of myelodysplastic syndromes.
@en
Molecular biology of myelodysplastic syndromes.
@nl
P2860
P1433
P1476
Molecular biology of myelodysplastic syndromes.
@en
P2093
Alan H Shih
Ross L Levine
P2860
P304
P356
10.1053/J.SEMINONCOL.2011.04.013
P577
2011-10-01T00:00:00Z